Adalvo has developed one of the broadest diabetes pipelines in the industry with an extensive range of therapeutic options.
Our diverse portfolio includes small molecules and peptide-based treatments, encompassing both oral and parenteral formulations, from short to long-acting range. This comprehensive approach makes diabetes care more manageable for patients worldwide.
Adalvo is dedicated to advancing diabetes care through scientific progress and rigorous research, as reflected in our portfolio.
Supported by a clear intellectual property (IP) strategy, we ensure sustainable growth and reinforce Adalvo's position as a leader in diabetes care.
According to IQVIA, our diabetes portfolio is valued at $85 billion, with a projected CAGR of 30% over the next three years.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!